Scotiabank analyst George Farmer lowered the firm’s price target on BioMarin to $78 from $95 and keeps a Sector Perform rating on the shares. While the firm is lowering its price target on the stock, Scotiabank believes the recent sell-off was probably overdone given the head start Voxzogo has as a potential treatment for short stature indication, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin price target lowered to $90 from $118 at Truist
- BioMarin price target lowered to $115 from $130 at BofA
- Ascendis Pharma price target raised to $190 from $180 at Oppenheimer
- BioMarin price target lowered to $85 from $100 at RBC Capital
- 3 Best Stocks to Buy Now, 9/17/2024, According to Top Analysts